Coach — Cardiology: Energy → Cardiovascular Phenotype
Plaque is often told as a morality play about cholesterol, fast heart rate on standing as a rate problem, and heart failure as a pump label. In the working hypothesis here they are closer to one story: energy demand outrunning mitochondrial capacity, and the body's emergency responses becoming permanent.
Safety first
The extended report puts the emergencies at the top: "Chest pain, sudden shortness of breath, syncope, stroke symptoms, or new severe orthostatic collapse are emergencies — call emergency services." It is equally clear about what the hypothesis is not: "Hypothesis language is not a statin-stop order, a procedure veto, a rate-control holiday, or a promise that plaque, POTS, hypertension, arrhythmia, or heart failure will reverse." And later: "This page does not invent peptide, HRT, or GLP-1 regimens, does not authorize stopping cardiology meds from a webpage, and does not promise plaque reversal." On the vessel-relaxing drugs: "Do not start, stop, or combine nitrates, PDE5 inhibitors, or other vasoactive drugs from this page."
In plain terms, nothing here is a reason to stop a statin, a PCSK9 inhibitor, an antiplatelet drug, a blood pressure medicine, a rate or rhythm drug, or a heart failure medicine, and nothing here is a reason to delay emergency care while thinking the case through. Megadose antioxidants, "cholesterol detox," and "POTS cures" are not engine repair. Familial hypercholesterolemia, high lipoprotein(a), established heart disease, fainting, and acute coronary syndromes are high-stakes situations that belong with specialists.
The cascade
The report starts from a rule it applies across chronic disease. When the energy the body needs exceeds what its mitochondria can produce, the system falls back on older, less efficient ways of making energy to keep going. Short bursts of that emergency mode can save the organism and can be undone. When the emergency mode becomes permanent, we call it disease. Restore capacity in time and much of the cascade can wind down. Fail to restore it, and the emergency-adapted pattern hardens. Read this way, the named syndromes of cardiology, plaque, fast heart rate on standing, thickened and scarred heart muscle, high pressure, unstable rhythm, are that chronic mode under different tissue clocks and loads. Lipids, heart rate, blood pressure, and ejection fraction are real and useful readings. They are not, in this hypothesis, independent origins of the failure.
Plaque as a repair record
The standard model of atherosclerosis is respected here. Particles carrying apolipoprotein B, the protein on LDL and related lipoproteins, become trapped in the artery wall; their cargo oxidizes; macrophages swallow it and become foam cells; inflammation builds plaque. Lowering apoB reduces events in randomized trials, in genetic studies, and in familial hypercholesterolemia. The report does not reject apoB measurement or lowering. It asks why retention, oxidation, and residual events happen where they do.
It points to gaps. Some people on ketogenic diets, the so-called lean mass hyper-responders, carry very high apoB for years with little plaque on imaging, while others progress quickly on modest numbers. The report argues that a large share of events persists despite aggressive apoB lowering. In familial hypercholesterolemia, a defective LDL receptor leaves cells short of cholesterol inside, which can divert the shared production pathway away from CoQ10, a carrier the energy chain depends on, toward making more cholesterol. And people who first improve their metabolism with food, daily rhythm, and resistance training often improve their lipid numbers along with everything else.
The proposed root is one layer upstream: mitochondria in the cells of the artery wall that underperform, leak reactive oxygen, and fail at quality control. When the lining cells' mitochondria falter, nitric oxide falls, sticky adhesion molecules rise, and the barrier weakens, so more particles get in and stay. Macrophages with failing mitochondria handle fat poorly and release danger signals that drive inflammation. Smooth-muscle cells with failing mitochondria die more readily and thin the plaque's protective cap. High insulin, rising to force glucose into resistant cells, also drives the liver to export more fat-carrying particles and blocks fat release from storage. In this reading, foam cells are desperate macrophages, not simple fat dumps, and plaque is a repair and walling-off record. Seed-oil fats built into membranes add to the damage by oxidizing into reactive aldehydes that injure the energy chain and the vessel lining.
Lipoprotein(a) fits the same picture. It is an apoB particle with an extra protein that resembles plasminogen, the precursor of the body's clot-dissolving enzyme, and interferes with clot breakdown, and it is a main carrier of oxidized phospholipids in the blood. In the report's terms it arrives as pre-damaged fuel, intensifying mitochondrial stress and pushing vessel-lining cells toward an inflammatory, sticky state. Its risk is real, and the report argues it is also modulated by the host: a resilient fuel-handling system may let even high lipoprotein(a) progress more slowly. Newer therapies that lower it can reduce the damaged cargo where specialists judge them indicated, while work on the engine addresses capacity. That is complementarity, not competition. The full treatment is in the extended report's atherosclerosis section.
Standing up
Postural orthostatic tachycardia syndrome, or POTS, is diagnosed by an excessive rise in heart rate on standing, at least 30 beats per minute in adults or 40 in adolescents, without a fall in blood pressure, with symptoms that ease on lying down. The usual approach of volume, compression, graded exercise, and targeted drugs is useful and, in the report's words, incomplete. It reframes the fast heart rate as the body's attempt to keep the brain supplied when stroke volume falls and energy-dependent control of vessels and nerves falters under gravity. On standing, a substantial volume of blood pools in the legs and abdomen. A metabolically robust person compensates quietly. In POTS, the tissues that matter most, vessel muscle, autonomic nerves, heart muscle, and brain, may lack the energy reserve to keep tone and output, and the heart races to make up the difference. The report links this to mitochondrial disruption after infection, including long COVID, and to overlap with chronic fatigue states.
The reasoning the report follows runs in order: safety first for fainting, chest pain, or neurological warning signs; then the volume and pooling measures a physician already endorses; then reconditioning that begins lying down before upright effort; then food that steadies fuel supply and lowers the load of easily oxidized fats; then morning light, dark nights, and consistent sleep. Mitochondrial cofactors appear in the report only as supports under supervision, never as a retail stack. POTS is varied. Autoimmunity, small-fiber nerve damage, pure deconditioning, and viral injury can dominate in different people. The shared question is whether energy economy is a limiting node, not a claim that every case is mitochondrial disease.
Muscle, pressure, and rhythm
Heart muscle cells have among the highest mitochondrial density of any cell. Chronic mismatch, from pressure overload, poor blood supply, high glucose, or dietary injury to the mitochondria, drives thickening that normalizes wall stress at a cost, and scarring that eventually stiffens or dilates the ventricle. That is explored in the essay on heart failure. The report reads part of the benefit of SGLT2 inhibitors in heart failure as a favorable shift in how heart muscle uses fuel, without turning that into prescribing advice. Long-standing high blood pressure is read as a scar of failed matching between supply and demand, centered on nitric oxide; see the essays on hypertension and the extended report on nitric oxide. Electrical stability is expensive too. Ion pumps and calcium handling are among the costliest continuous jobs in heart tissue, and when energy supply falters, excitability and conduction become less stable. The extended report on electrophysiology and arrhythmia takes that up in depth, and specialists still own devices, anticoagulation, and ablation timing. Related essays look at the lungs and at arterial and venous occlusions.
Engine before dashboard
None of this competes with what cardiology does well: reperfusion, devices, antiplatelet and anticoagulant care, pressure and rate control, lipid lowering where indicated, rehabilitation, and the drug classes that improve heart failure outcomes. The report relocates the order of questions, not the minutes that matter. Its translation into daily life is hypothesis, not rehabilitation orders: food that supports clean fat burning and avoids chronically high insulin and seed-oil-dominated eating; morning outdoor light, consistent sleep, and dim evenings; and progressive resistance and cardiorespiratory work, with a carefully progressive start lying down when standing is the problem. Grip, fitness, lean mass, and recovery are honest readings of the engine beside lipids, pressure, and heart rate; the common measures of capacity are described elsewhere. A better apoB or a quieter standing heart rate on a collapsing pattern of sleep and fitness is an incomplete win. Ignoring a dangerous number is the opposite error.
This is a working hypothesis, not a trial verdict that mitochondria-first strategies outperform guideline lipid lowering, heart failure care, or autonomic specialty care on their own. It does not deny apoB biology, oxidized phospholipids, thrombosis, ischemia, or structural heart disease, or the value of the treatments built on them when they are indicated. Valve disease is not covered. Cardiology still owns the emergency.
For the full argument, read the extended report on cardiology. The short version is in the lessons. Talk with your own physician before changing medications or supplements.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.
See the notice at the top of this page. Working hypothesis, not medical advice.